BioNTech’s $1 Billion Share Buyback Begins as Factory Closures and Founder Exit Reshape the Group

BioNTech starts a $1B share repurchase program through 2027 as it slims COVID operations, closes four sites, and bets heavily on cancer drug Pumitamig.

BioNTech formally launched its $1 billion share repurchase programme on Thursday, a move designed to signal confidence in the company’s long-term prospects even as it navigates a painful restructuring. The buyback, which will run through May 2027, comes as the Mainz-based biotech slims down its COVID-era footprint and pivots aggressively toward oncology.

The stock, however, failed to catch a bid. Shares slipped nearly 3% to €78.65 on Thursday, extending a weekly decline of almost 11%. The equity now trades well below both its 200-day and 50-day moving averages, reflecting lingering investor scepticism about the transition ahead.

Red ink deepens as COVID revenue evaporates

First-quarter results laid bare the scale of the challenge. Revenue slumped to €118.1 million from roughly €183 million a year earlier, as demand for COVID-19 vaccines continues to fade. The net loss ballooned to $622 million, or €532 million depending on the reporting currency, as research spending surged to around $651 million (€557 million).

BioNTech’s cash pile remains formidable at €16.8 billion, providing ample runway for the transformation. But the burn rate is accelerating: the company is pouring capital into its oncology pipeline while simultaneously winding down legacy operations.

Four sites to close, half a billion in annual savings

The restructuring is sweeping. By the end of 2027, BioNTech will shutter its facilities in Idar-Oberstein, Marburg, and Tübingen, along with its plant in Singapore, which is set to cease operations in early 2027. The company is exploring sales for all four sites.

The goal is to slash annual costs by roughly €500 million from 2029 onward. From late 2026, partner Pfizer will assume full responsibility for manufacturing COVID vaccines, freeing up further resources. Every euro saved is being redirected into the oncology pipeline, where BioNTech has placed its biggest bet yet.

Five pivotal cancer trials now underway

The centrepiece of that bet is Pumitamig, a bispecific antibody targeting aggressive tumour types including triple-negative breast cancer and lung cancer. BioNTech recently launched five registration-enabling studies for the drug, with initial Phase III readouts expected later this year.

The company is also exploring combination therapies, working with partners such as Boehringer Ingelheim. Analysts are watching closely: positive data could transform the investment case, while setbacks would leave the stock exposed.

Founder departure adds another layer of uncertainty

Adding to the upheaval, BioNTech’s founders Ugur Sahin and Özlem Türeci are set to leave the company at the end of 2026. The pair plan to establish a new venture focused on mRNA technologies, effectively spinning off the platform that made BioNTech a household name during the pandemic.

The founder exit, combined with an ongoing patent dispute with Arbutus, creates a complex backdrop for the shares. Management has reaffirmed its full-year revenue guidance of between $2.3 billion and $2.6 billion (€2.0 billion to €2.3 billion), but the path to that target is strewn with operational, legal, and leadership hurdles.